Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.

Luc CabelDan RosenblumFlorence LereboursEtienne BrainDelphine LoiratMattias BergqvistPaul CottuAnne DonnadieuAnne BethuneNicolas KiavueManuel RodriguesJean-Yves PiergaMarie-Laure TanguyFrançois-Clément Bidard

Published in: Breast cancer research : BCR (2020)

This study demonstrates the clinical validity of pTKa as a new circulating prognostic marker in ER+/HER2- MBC patients treated with endocrine therapy and palbociclib.

Keyphrases

metastatic breast cancer
estrogen receptor
endoplasmic reticulum
stem cells
mesenchymal stem cells